Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study

Thibaut Sanglier,Jinjoo Shim, Neil Lamarre, Claudia Peña-Murillo,Vincent Antao,Filippo Montemurro

The Breast（2023）

引用 1|浏览7

暂无评分

摘要

•Breast cancer with brain metastases (BCBM) has been associated with lower survival.•T-DM1 improves survival vs lapatinib + capecitabine in real-world HER2+ BCBM patients.•Time to next treatment was also prolonged with T-DM1 vs lapatinib + capecitabine.•T-DM1 is an effective and clinically relevant option for patients with HER2+ BCBM.

查看译文

关键词

Trastuzumab emtansine,HER2-Positive metastatic breast cancer,Brain metastases,Lapatinib plus capecitabine,Real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要